Physician profile
Strick Woods
NPI 1568454247
$9,442.07
in general payments reported to CMS, 2019-2025
37 companies · $2,144 in 2025
The $2,144 reported for 2025 was more than what 94% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,821 · 2020: $431 · 2021: $494 · 2022: $973 · 2023: $1,825 · 2024: $1,754 · 2025: $2,144.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,723.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,723.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,306.11 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Janssen Biotech, INC. | $1,155.40 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Pfizer INC. | $857.67 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $820.29 | 2019-2024 | Xifaxan, Trulance |
| Celgene Corporation | $748.03 | 2021-2024 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $565.25 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Genzyme Corporation | $438.07 | 2022-2025 | |
| Madrigal Pharmaceuticals | $360.56 | 2025 | Rezdiffra |
| Qol Medical, LLC | $288.39 | 2019-2025 | Sucraid, Sucraid |
| Ipsen Biopharmaceuticals, INC | $203.12 | 2024-2025 | Iqirvo |
| Ardelyx, INC. | $188.44 | 2022-2025 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $136.29 | 2022-2025 | Dupixent |
| Ironwood Pharmaceuticals, INC | $134.54 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $130.04 | 2022-2023 | |
| Allergan, INC. | $125.11 | 2019 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $98.77 | 2021-2025 | Omvoh |
| Ferring Pharmaceuticals INC. | $95.55 | 2019-2024 | Rebyota |
| Phathom Pharmaceuticals, INC. | $85.22 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $84.07 | 2019-2023 | Dificid |
| Intercept Pharmaceuticals, INC. | $81.23 | 2019-2025 | |
| Exact Sciences Corporation | $79.50 | 2023-2025 | Cologuard Collection Kit |
| Ucb, INC. | $69.42 | 2019 | |
| Gilead Sciences, INC. | $68.94 | 2020-2025 | |
| Aimmune Therapeutics, INC. | $68.68 | 2025 | Zenpep |
| Daiichi Sankyo INC. | $55.89 | 2019-2023 | Injectafer |
| Endo Pharmaceuticals INC. | $29.46 | 2019 | |
| Nestle Healthcare Nutrition INC. | $20.37 | 2022 | |
| Redhill Biopharma INC. | $20.25 | 2022 | |
| Novo Nordisk INC | $18.08 | 2025 | Wegovy |
| Concordia Pharmaceuticals INC. | $17.90 | 2019 | |
| Amgen INC. | $17.35 | 2021 | |
| Pentax of America, INC. | $17.01 | 2020-2021 | |
| Braintree Laboratories, INC. | $16.36 | 2023 | Sutab |
| Fresenius Kabi USA, LLC | $15.02 | 2023 | |
| Shionogi INC | $14.49 | 2019 | |
| Portola Pharmaceuticals, LLC | $11.20 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$77,759.52 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Strick Woods listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.